source
- Sensorion drops OTOF gene therapy to focus on GJB2-targeted hearing loss candidate after Regeneron approvalSensorion said it is ending development of its gene therapy SENS-501 for OTOF related hearing loss after a strategic review. The review concluded that the competitive landscape had changed signific…
- HHS gives measured response to alcohol risk study as health news roundup covers soda link, NIH debate, diabetes apology and DOJ lawsuitThe Department of Health and Human Services issued a cautious reaction to a recent paper that examined the relationship between alcohol consumption and health risks, noting the need for further evi…